---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046109"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:19:25.498253+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CVRx Q1 revenue $12.3M (+15% YoY); net loss narrows; guides FY2025 rev $55-58M

## Summary
- Total revenue $12.3M (+15% YoY); U.S. HF revenue $11.1M (+14%) on 353 implants.
- Net loss $13.8M ($0.53/share) vs $22.2M ($1.04) in Q1 2024; cash $102.7M.
- FY2025 revenue guidance $55-58M; Q2 revenue expected $13-14M.
- Active U.S. implanting centers 227 (+19% YoY); gross margin 84%.
- Real-world evidence: 85% reduction in HF hospital visits (Premier Healthcare Database).

## SEC filing metadata
- accession: 0001104659-25-046109
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465925046109/0001104659-25-046109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465925046109/tm2514410d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046109
- JSON: https://secwatch.observer/filing/0001104659-25-046109.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.